1h Free Analyst Time
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 33 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2022, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 8, 1, 11, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Musculoskeletal Disorders, Respiratory, Cardiovascular and Oncology which include indications Obesity, Type 2 Diabetes, Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Diastolic Heart Failure, Fibrosis, Idiopathic Pulmonary Fibrosis, Liver Fibrosis, Neuroendocrine Cancer, Obstructive Sleep Apnea, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Metabolic Disorders.
Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
- The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
- 3B Pharmaceuticals GmbH
- Amgen Inc
- Antag Therapeutics ApS
- Bainan Biotech ApS
- Carmot Therapeutics Inc
- D&D Pharmatech Co Ltd
- Eli Lilly and Co
- Gmax Biopharm LLC
- Great Bay Bio Holdings Ltd
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Kariya Pharmaceuticals IVS
- Longevity Biotech Inc
- Novo Nordisk AS
- Onegene Biotechnology Inc
- Sciwind Biosciences Co Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- Viking Therapeutics Inc
- Zealand Pharma AS
- Zhejiang Doer Biologics Corp
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
- (semaglutide + GIP analogue) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- 3B-401 - Drug Profile
- Product Description
- Mechanism Of Action
- AMG-133 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CT-868 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DAJC-1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DD-03 - Drug Profile
- Product Description
- Mechanism Of Action
- DR-10624 - Drug Profile
- Product Description
- Mechanism Of Action
- DR-10625 - Drug Profile
- Product Description
- Mechanism Of Action
- DR-10627 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DR-10628 - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GIPR AGONIST LA II - Drug Profile
- Product Description
- Mechanism Of Action
- GMA-106 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HM-15211 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HS-20094 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KP-405 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LBT-6030 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LY-3437943 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LY-3493269 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LY-3537021 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OGB-21501 - Drug Profile
- Product Description
- Mechanism Of Action
- Peptides to Antagonize GIPR for Obesity - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Peptide to Activate GIPR for Type I Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- THDBH-120 - Drug Profile
- Product Description
- Mechanism Of Action
- THDBH-121 - Drug Profile
- Product Description
- Mechanism Of Action
- tirzepatide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VK-2735 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XW-003 + XW-017 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ZP-6590 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
- Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
- Featured News & Press Releases
- Jul 07, 2022: Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide”
- Jun 10, 2022: Lilly eyes weight loss arena for diabetes drug tirzepatide after positive data
- Jun 08, 2022: Sciwind Biosciences to present data from its GLP-1 Program at The International Liver Congress EASL 2022
- Jun 06, 2022: New analyses of Mounjaro (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's 82nd Scientific Sessions
- Jun 04, 2022: SURMOUNT-1 Study Finds Individuals with Obesity Lost up to 22.5% of their Body Weight when Taking Tirzepatide
- Jun 04, 2022: Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
- Jun 03, 2022: Tirzepatide slowed progression of chronic kidney disease in patients with type 2 diabetes with increased cardiovascular risk
- May 16, 2022: Lilly’s Mounjaro receives FDA approval for type 2 diabetes treatment
- Apr 28, 2022: Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
- Apr 26, 2022: AMRA Medical's MRI-based body composition measurements used in Lilly's SURPASS-3 tirzepatide sub-study
- Apr 08, 2022: Announcement of Huadong Medicine on obtaining the approval notice of drug clinical trial for its holding subsidiary
- Jan 10, 2022: Viking Therapeutics announces initiation of phase 1 clinical trial of VK2735, company's lead dual GLP-1/GIP receptor agonist
- Nov 11, 2021: Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
- Nov 01, 2021: Viking Therapeutics presents preclinical data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
- Oct 20, 2021: Lilly’s tirzepatide reduces body weight in Phase III type 2 diabetes trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3B Pharmaceuticals GmbH
- Amgen Inc
- Antag Therapeutics ApS
- Bainan Biotech ApS
- Carmot Therapeutics Inc
- D&D Pharmatech Co Ltd
- Eli Lilly and Co
- Gmax Biopharm LLC
- Great Bay Bio Holdings Ltd
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Kariya Pharmaceuticals IVS
- Longevity Biotech Inc
- Novo Nordisk AS
- Onegene Biotechnology Inc
- Sciwind Biosciences Co Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- Viking Therapeutics Inc
- Zealand Pharma AS
- Zhejiang Doer Biologics Corp
